Market Cap 12.46B
Revenue (ttm) 943.71M
Net Income (ttm) -381.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -40.41%
Debt to Equity Ratio 0.00
Volume 1,360,300
Avg Vol 2,017,584
Day's Range N/A - N/A
Shares Out 165.26M
Stochastic %K 60%
Beta 0.38
Analysts Strong Sell
Price Target $103.60

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
S144
S144 May. 13 at 5:52 AM
$IONS Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript https://seekingalpha.com/article/4903347-ionis-pharmaceuticals-inc-ions-presents-at-bank-of-america-global-healthcare-conference-2026 Btw: IONS is +126% in 1Y
0 · Reply
CapitalMonk
CapitalMonk May. 11 at 10:52 PM
$IONS Price: $75.38 (-0.44%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.14% RSI: 52.9 | Momentum: Moderate Volume: -17.5% vs avg Volatility: 1.47% Support: $71.18 | Resistance: $77.76 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:53 PM
$IONS Current Stock Price: $76.79 Contracts to trade: $77.5 IONS May 15 2026 Call Entry: $0.35 Exit: $0.68 ROI: 96% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:32 PM
$IONS Current Stock Price: $76.43 Contracts to trade: $77.5 IONS May 15 2026 Call Entry: $0.90 Exit: $1.70 ROI: 89% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
onefryshy
onefryshy May. 5 at 7:38 PM
$IONS I especially like the fact that nobody is following this stock because I think it could be bought out at some point.
4 · Reply
Ccg_
Ccg_ May. 4 at 11:17 PM
$IONS what is that ah?
0 · Reply
Monkey7779192
Monkey7779192 May. 2 at 5:26 PM
$IONS Odds of approval in June 30? Has puts huge volume.
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 5:22 PM
$IONS Current Stock Price: $75.54 Contracts to trade: $75.0 IONS May 15 2026 Call Entry: $1.55 Exit: $2.57 ROI: 66% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
IN0V8
IN0V8 Apr. 30 at 2:21 PM
$IONS Buy Barclays raises target price to $115 from $106 H.C. Wainwright raises target price to $125 from $120 Leerink Partners raises target to $114 from $111 Stifel raises target price to $86 from $83
0 · Reply
Djohn2012
Djohn2012 Apr. 29 at 2:57 PM
$IONS Huge beat! Why is this not flying?
1 · Reply
Latest News on IONS
Ionis to host 2026 virtual Annual Meeting of Stockholders

May 4, 2026, 7:05 AM EDT - 9 days ago

Ionis to host 2026 virtual Annual Meeting of Stockholders


Ionis to present at upcoming investor conferences

May 1, 2026, 7:05 AM EDT - 12 days ago

Ionis to present at upcoming investor conferences


Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 14 days ago

Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026


Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)

2026-04-29T11:41:17.000Z - 14 days ago

Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)


Ionis Pharmaceuticals initiated with a Buy at Canaccord

2026-04-21T09:05:11.000Z - 22 days ago

Ionis Pharmaceuticals initiated with a Buy at Canaccord


Ionis Pharmaceuticals initiated with a Buy at Canaccord

2026-04-20T20:43:15.000Z - 23 days ago

Ionis Pharmaceuticals initiated with a Buy at Canaccord


Ionis to hold first quarter 2026 financial results webcast

Apr 15, 2026, 7:05 AM EDT - 4 weeks ago

Ionis to hold first quarter 2026 financial results webcast


Ionis Pharmaceuticals management to meet with Oppenheimer

2026-04-02T14:42:38.000Z - 5 weeks ago

Ionis Pharmaceuticals management to meet with Oppenheimer


Ionis announces changes to Board of Directors

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Ionis announces changes to Board of Directors


Ionis Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:30 AM EST - 2 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q4 2025


Biogen Completes Acquisition of Alcyone Therapeutics

Nov 14, 2025, 4:05 PM EST - 6 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

BIIB


Ionis Pharmaceuticals Transcript: Study Update

Nov 8, 2025, 3:00 PM EST - 6 months ago

Ionis Pharmaceuticals Transcript: Study Update


Ionis Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 29, 2025, 11:30 AM EDT - 7 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q3 2025


Ionis to hold third quarter 2025 financial results webcast

Oct 16, 2025, 7:05 AM EDT - 7 months ago

Ionis to hold third quarter 2025 financial results webcast


Ionis Pharmaceuticals Transcript: Innovation Day 2025

Oct 7, 2025, 8:30 AM EDT - 7 months ago

Ionis Pharmaceuticals Transcript: Innovation Day 2025


Ionis' brain disorder drug shows promise in clinical trial

Sep 22, 2025, 7:10 AM EDT - 8 months ago

Ionis' brain disorder drug shows promise in clinical trial


Ionis to host investors and analysts for Innovation Day 2025

Sep 8, 2025, 4:00 PM EDT - 8 months ago

Ionis to host investors and analysts for Innovation Day 2025


Is The 35% Rally In IONS Stock Just The Beginning?

Sep 3, 2025, 10:41 AM EDT - 9 months ago

Is The 35% Rally In IONS Stock Just The Beginning?


Ionis Pharmaceuticals Transcript: Study Result

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Ionis Pharmaceuticals Transcript: Study Result


Ionis Pharmaceuticals Transcript: FDA Announcement

Aug 21, 2025, 12:15 PM EDT - 9 months ago

Ionis Pharmaceuticals Transcript: FDA Announcement


US FDA approves Ionis' drug for rare genetic disorder

Aug 21, 2025, 11:58 AM EDT - 9 months ago

US FDA approves Ionis' drug for rare genetic disorder


Ionis Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 30, 2025, 11:30 AM EDT - 10 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q2 2025


S144
S144 May. 13 at 5:52 AM
$IONS Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript https://seekingalpha.com/article/4903347-ionis-pharmaceuticals-inc-ions-presents-at-bank-of-america-global-healthcare-conference-2026 Btw: IONS is +126% in 1Y
0 · Reply
CapitalMonk
CapitalMonk May. 11 at 10:52 PM
$IONS Price: $75.38 (-0.44%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.14% RSI: 52.9 | Momentum: Moderate Volume: -17.5% vs avg Volatility: 1.47% Support: $71.18 | Resistance: $77.76 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:53 PM
$IONS Current Stock Price: $76.79 Contracts to trade: $77.5 IONS May 15 2026 Call Entry: $0.35 Exit: $0.68 ROI: 96% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:32 PM
$IONS Current Stock Price: $76.43 Contracts to trade: $77.5 IONS May 15 2026 Call Entry: $0.90 Exit: $1.70 ROI: 89% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
onefryshy
onefryshy May. 5 at 7:38 PM
$IONS I especially like the fact that nobody is following this stock because I think it could be bought out at some point.
4 · Reply
Ccg_
Ccg_ May. 4 at 11:17 PM
$IONS what is that ah?
0 · Reply
Monkey7779192
Monkey7779192 May. 2 at 5:26 PM
$IONS Odds of approval in June 30? Has puts huge volume.
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 5:22 PM
$IONS Current Stock Price: $75.54 Contracts to trade: $75.0 IONS May 15 2026 Call Entry: $1.55 Exit: $2.57 ROI: 66% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
IN0V8
IN0V8 Apr. 30 at 2:21 PM
$IONS Buy Barclays raises target price to $115 from $106 H.C. Wainwright raises target price to $125 from $120 Leerink Partners raises target to $114 from $111 Stifel raises target price to $86 from $83
0 · Reply
Djohn2012
Djohn2012 Apr. 29 at 2:57 PM
$IONS Huge beat! Why is this not flying?
1 · Reply
jcooptechit
jcooptechit Apr. 29 at 1:43 PM
$CELZ TIGHTENING AND NEXT LEG COULD IGNITE FAST CELZ is tightening into a clean bullish structure with a defined base and rising trend: this is where momentum setups begin. 📊 TECHNICAL BREAKDOWN: ▫️ Demand Zone: $1.90 – $2.05 (strong accumulation + multiple holds) ▫️ Support: $2.05 - $2.16 ▫️ Pivot Zone: $2.16 – $2.32 ▫️ Resistance: $2.50 ▫️ Next Resistance: $2.72 ▫️ Breakout Level: $2.72+ 📈 CHART STRUCTURE: • Higher lows forming/ uptrend developing • Descending trendline already broken • Consolidation above demand = strong base • Price holding key mid-range levels 🧠 KEY CATALYSTS: ▫️ Ongoing clinical trials (CELZ-201) ▫️ Positive interim data already reported ▫️ Upcoming updates = news-driven momentum potential ▫️ Regenerative medicine narrative ($90B+ market) CELZ sitting at a key inflection. watch $2.32 - $2.72 closely. This is where the next move can accelerate. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $REGN $VRTX $ALNY $IONS
0 · Reply
Fingerlickengood
Fingerlickengood Apr. 29 at 1:18 PM
$CDXS $RNA $MRK $IONS https://www.globenewswire.com/news-release/2026/04/29/3283814/24825/en/Codexis-to-share-RNA-manufacturing-advances-at-TIDES-USA.html
2 · Reply
JFais
JFais Apr. 29 at 11:58 AM
$IONS was on the fence but missed this one entirely, as good as a value setup in biotech as there ever was
0 · Reply
JFais
JFais Apr. 29 at 11:56 AM
$IONS increasing annual peak sales for olezarsen from $2 billion to $3 billion- reflects increasing confidence in the sHTG market opportunity (bodes well for $ARWR's plozasiran/Redemplo)
0 · Reply
JFais
JFais Apr. 29 at 11:47 AM
$KALV- sold too soon, congrats to longs on the Chiesi buyout 👏($1.9B valuation a solid exit considering coming competition like $PHVS $IONS)
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 29 at 11:08 AM
$IONS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.56 up 39.78% YoY • Reported revenue of $246M up 86.91% YoY • Ionis improved its full year 2026 total revenue guidance to $875-900 million and lowered its non-GAAP operating loss guidance to $425-475 million, maintaining cash, cash equivalents, and short-term investments above $1.6 billion.
0 · Reply
zerodayrounder
zerodayrounder Apr. 28 at 7:57 PM
from $GSK Q4 report 2 major product approvals expected -- bepirovirsen PDUFA date set today for October 26, 2026 --- partner $IONS $12B market cap too big to acquire tebipenem is next June 18.. with $SPRO $160 million market cap out of the readouts -- jemperli (contract dispute with $ANAB) one would think GSK would want to fully own blockbusters
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 23 at 9:56 PM
$IONS Share Price: $74.11 Contract Selected: Aug 21, 2026 $75 Calls Buy Zone: $4.67 – $5.78 Target Zone: $8.19 – $10.00 Potential Upside: 65% ROI Time to Expiration: 119 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
johnnygogogo
johnnygogogo Apr. 23 at 8:29 PM
$ARWR I know the valuations are different but for the record, Arrowhead has a bigger PPS than $IONS cc @skeezbag 🤩
2 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 21 at 3:55 PM
$IONS Zilganersen's commercial success hinges primarily on execution beyond the trial rather than its strong clinical evidence. The real bottleneck isn't payer resistance—it's the diagnostic challenge. Patients frequently misdiagnosed as multiple sclerosis or atypical parkinsonism, getting an accurate diagnosis remains the biggest obstacle to reaching potential patients and driving revenue. $BIIB $SRPT $BMRN #AlexanderDisease Read more: www.clinicaltrialsdaily.com/zilganersen-aso-alexander-disease-pdufa/
0 · Reply
Quantumup
Quantumup Apr. 21 at 2:26 PM
Morgan Stanley⬆️ $ARWR to Overweight; $100 from Equal-weight; $78, plus⬆️plozasiran's sHTG revenue estimates to adj-peak sales of $3.2B. $IONS $LLY $REGN Here's what Morgan Stanley said in its note: https://x.com/Quantumup1/status/2046595809731289186?s=20
0 · Reply
Fingerlickengood
Fingerlickengood Apr. 21 at 1:57 PM
$CDXS $IONS " In February 2025, Codexis appointed Dr. Arthur Levin to its Strategic Advisory Board. Dr. Levin was a pioneer at Ionis Pharmaceuticals, where he led research and development and played a central role in the birth of the antisense oligonucleotide (ASO) field." Pivitol studies from Ionis today, coincidendally Zilganersen (formerly ION373) is an ASO! https://ir.ionis.com/news-releases/news-release-details/ionis-presents-new-data-pivotal-study-zilganersen-alexander
0 · Reply